| 4.62 -0.015 (-0.32%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.6 | 1-year : | 6.54 |
| Resists | First : | 4.79 | Second : | 5.6 |
| Pivot price | 4.54  |
|||
| Supports | First : | 4.11 | Second : | 3.7 |
| MAs | MA(5) : | 4.6 | MA(20) : | 4.43 |
| MA(100) : | 4.33 |
MA(250) : | 4.4 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 75.1 |
D(3) : | 80 |
| RSI | RSI(14): 58.5 |
|||
| 52-week | High : | 6.17 | Low : | 3.08 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CTKB ] has closed below upper band by 31.2%. Bollinger Bands are 52.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.66 - 4.69 | 4.69 - 4.72 |
| Low: | 4.48 - 4.51 | 4.51 - 4.54 |
| Close: | 4.57 - 4.62 | 4.62 - 4.67 |
Cytek Biosciences, Inc. is a company dedicated to cell analysis solutions, offering advanced tools that facilitate scientific progress in both biomedical research and clinical settings. Their primary offerings include the Aurora and Northern Lights spectrum flow cytometers. These instruments conduct comprehensive cell analysis by leveraging fluorescence signatures from multiple lasers to differentiate between various fluorescent tags on individual cells. Complementing these, the Aurora Cell Sorter system utilizes full spectrum profiling technology to broaden the range of potential applications in cell analysis. Beyond instrumentation, Cytek provides essential reagents and kits. These include cFluor reagents, which are antibodies conjugated with fluorochromes, specifically designed to identify target cells for analysis on their systems. They also offer a 25-color immunoprofiling assay, a ready-to-use solution for pinpointing major human immune cell subpopulations like TBNK cells, monocytes, dendritic cells, and basophils. To streamline laboratory operations, the company offers automated micro-sampling and sample loader systems. These automated plate loaders are engineered to integrate seamlessly with the Aurora and Northern Lights systems. The intuitive SpectroFlo software accompanies these systems, simplifying the workflow from quality control through to data analysis. Cytek also provides comprehensive customer support resources. Cytek's diverse client base includes pharmaceutical and biopharmaceutical companies, academic research institutions, and clinical research organizations. The company distributes its products through a direct sales force and dedicated support teams in North America, Europe, China, and the Asia-Pacific region. Additionally, it partners with distributors and sales agents to serve markets across European, Latin American, Middle Eastern, and other Asia-Pacific countries. Originally established in 1992 as Cytoville, Inc., the company officially adopted the name Cytek Biosciences, Inc. in August 2015. Its corporate headquarters are situated in Fremont, California.
Wed, 15 Jul 2026
Cytek Biosciences Opens Bellevue Innovation Center to Advance R&D and Customer Engagement - Quiver Quantitative
Wed, 15 Jul 2026
Cytek's Valerie Barnett exits as Chief Legal Officer; consulting role agreed - TradingView
Wed, 15 Jul 2026
Cytek Biosciences (Nasdaq: CTKB) sets severance and consulting terms - Stock Titan
Tue, 14 Jul 2026
BlackRock, Inc. Reduces Stake in Cytek Biosciences Inc - GuruFocus
Wed, 08 Jul 2026
BlackRock (NYSE: CTKB) holds 7.2% — 9.36M shares of Cytek Biosciences - Stock Titan
Sun, 28 Jun 2026
Price to earnings forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 129 (M) |
| Shares Float | 97 (M) |
| Held by Insiders | 8.4 (%) |
| Held by Institutions | 67.4 (%) |
| Shares Short | 3,510 (K) |
| Shares Short P.Month | 7,300 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.53 |
| Profit Margin | -36.3 % |
| Operating Margin | -41.9 % |
| Return on Assets (ttm) | -5.9 % |
| Return on Equity (ttm) | -21 % |
| Qtrly Rev. Growth | 6.5 % |
| Gross Profit (p.s.) | 0.81 |
| Sales Per Share | 1.58 |
| EBITDA (p.s.) | -0.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | 6 (M) |
| PE Ratio | -7.97 |
| PEG Ratio | 0 |
| Price to Book value | 1.81 |
| Price to Sales | 2.92 |
| Price to Cash Flow | -81.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|